These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26660394)

  • 21. Expression of the adaptor protein Lnk in leukemia cells.
    Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
    Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LNK mutations in familial myeloproliferative neoplasms.
    Rumi E; Harutyunyan AS; Pietra D; Feenstra JD; Cavalloni C; Roncoroni E; Casetti I; Bellini M; Milanesi C; Renna MC; Gotti M; Astori C; Kralovics R; Cazzola M
    Blood; 2016 Jul; 128(1):144-5. PubMed ID: 27216218
    [No Abstract]   [Full Text] [Related]  

  • 23. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
    Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
    Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Lnk adaptor protein: a key regulator of normal and pathological hematopoiesis.
    Velazquez L
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):415-29. PubMed ID: 22990499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
    Bersenev A; Wu C; Balcerek J; Tong W
    J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice.
    Akada H; Akada S; Hutchison RE; Mohi G
    Haematologica; 2012 Sep; 97(9):1389-93. PubMed ID: 22371173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and functional analysis of target recognition by the lymphocyte adaptor protein LNK.
    Morris R; Zhang Y; Ellyard JI; Vinuesa CG; Murphy JM; Laktyushin A; Kershaw NJ; Babon JJ
    Nat Commun; 2021 Oct; 12(1):6110. PubMed ID: 34671038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
    Zhan H; Kaushansky K
    Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms.
    Ikeda K; Ogawa K; Takeishi Y
    Fukushima J Med Sci; 2012; 58(2):91-100. PubMed ID: 23237864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
    Grinfeld J; Godfrey AL
    Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.
    Louria-Hayon I; Frelin C; Ruston J; Gish G; Jin J; Kofler MM; Lambert JP; Adissu HA; Milyavsky M; Herrington R; Minden MD; Dick JE; Gingras AC; Iscove NN; Pawson T
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20599-604. PubMed ID: 24297922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK-2 mutations and their relevance to myeloproliferative disease.
    Levine RL; Gilliland DG
    Curr Opin Hematol; 2007 Jan; 14(1):43-7. PubMed ID: 17133099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.
    Martin SE; Sausen M; Joseph A; Kingham BF; Martin ES
    Cancer Genet; 2012 Jun; 205(6):295-303. PubMed ID: 22749035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T784C LNK gene polymorphism and the risk of myeloproliferative disorders.
    Olkhovskiy IA; Gorbenko AS; Stolyar MA; Vasiliev EV; Mikhalev MA; Tabakova KA
    Leuk Lymphoma; 2019 Jan; 60(1):277-278. PubMed ID: 29749755
    [No Abstract]   [Full Text] [Related]  

  • 40. Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis.
    Albiero E; Madeo D; Ruggeri M; Bernardi M; Giorgetti A; Rodeghiero F
    Br J Haematol; 2008 Sep; 142(6):986-90. PubMed ID: 18671703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.